Circulating Cancer Stem Cells Expressing EpCAM/CD90 in Hepatocellular Carcinoma: A Pilot Study for Predicting Tumor Recurrence after Living Donor Liver Transplantation.
Hyeo Seong HwangJeong Eun YooDai Hoon HanJin Sub ChoiJae Geun LeeDong Jin JooMyoung Soo KimSoon Il KimGi-Hong ChoiYoung Nyun ParkPublished in: Gut and liver (2021)
EpCAM+/CD90+ CTCs can be used preoperatively and 1 day after LDLT as key biological markers in LT candidate selection and post-LDLT management.